Show simple item record

dc.contributor.authorKristan, Megan M
dc.contributor.authorKim, Yoon K
dc.contributor.authorNelson, Toby
dc.contributor.authorMoxley, Meaghan C
dc.contributor.authorYip, Terry Cheuk-Fung
dc.contributor.authorMunir, Kashif
dc.contributor.authorMalek, Rana
dc.date.accessioned2021-07-29T18:14:10Z
dc.date.available2021-07-29T18:14:10Z
dc.date.issued2021-06-06
dc.identifier.urihttp://hdl.handle.net/10713/16264
dc.description.abstractObjective: Diabetes is an independent risk factor for severe SARS-CoV-2 infections. This study aims to elucidate the risk factors predictive of more severe outcomes in patients with diabetes by comparing the clinical characteristics of those requiring inpatient admissions with those who remain outpatient. Methods: A retrospective review identified 832 patients—631 inpatients and 201 outpatients—with diabetes and a positive SARS-CoV-2 test result between March 1 and June 15, 2020. Comparisons between the outpatient and inpatient cohorts were conducted to identify risk factors associated with severity of disease determined by admission rate and mortality. Previous dipeptidyl peptidase 4 inhibitor use and disease outcomes were analyzed. Results: Risk factors for increased admission included older age (odds ratio [OR], 1.04 [95% CI, 1.01-1.06]; P = .003), the presence of chronic kidney disease (OR, 2.32 [1.26-4.28]; P = .007), and a higher hemoglobin A1c at the time of admission (OR, 1.25 [1.12-1.39]; P < .001). Lower admission rates were seen in those with commercial insurance. Increased mortality was seen in individuals with older age (OR, 1.09 [1.07-1.11]; P < .001), higher body mass index number (OR, 1.04 [1.01-1.07]; P = .003), and higher hemoglobin A1c value at the time of diagnosis of COVID-19 (OR, 1.12 [1.01-1.24]; P = .028) and patients requiring hospitalization. Lower mortality was seen in those with hyperlipidemia. Dipeptidyl peptidase 4 inhibitor use prior to COVID-19 infection was not associated with a decreased hospitalization rate. Conclusion: This retrospective review offers the first analysis of outpatient predictors for admission rate and mortality of COVID-19 in patients with diabetes. © 2021 AACEen_US
dc.description.urihttps://doi.org/10.1016/j.eprac.2021.05.011en_US
dc.description.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179716/en_US
dc.language.isoenen_US
dc.publisherElsevier B.V.en_US
dc.relation.ispartofEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologistsen_US
dc.rightsCopyright © 2021 AACE. Published by Elsevier Inc. All rights reserved.en_US
dc.subjectCOVID-19en_US
dc.subjectDPP-4 inhibitoren_US
dc.subjecthealth disparitiesen_US
dc.subjecthospitalizationen_US
dc.subjectrisk factorsen_US
dc.titlePredictors of Severe COVID-19 in Patients With Diabetes: A Multicenter Reviewen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.eprac.2021.05.011
dc.identifier.pmid34102308
dc.source.countryUnited States
dc.source.countryUnited States


Files in this item

Thumbnail
Name:
Publisher version

This item appears in the following Collection(s)

Show simple item record